- Home
- IMMX
IMMX
Immix Biopharma Inc.
as 11-21-2024 4:00pm EST
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | LOS ANGELES |
| Market Cap: | 46.8M | IPO Year: | 2021 |
| Target Price: | $7.00 | AVG Volume (30 days): | 89.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.83 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.26 - $7.75 | Next Earning Date: | 11-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 200.00% |
Latest Immix Biopharma Inc. News
IMMX Breaking Stock News: Dive into IMMX Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 months ago
Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2
GlobeNewswire
2 months ago
Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board
Argus Research
3 months ago
Daily – Vickers Top Insider Picks for 09/06/2024
Argus Research
3 months ago
Daily – Vickers Top Insider Picks for 09/05/2024
Argus Research
3 months ago
Daily – Vickers Top Insider Picks for 09/04/2024
Argus Research
3 months ago
Daily – Vickers Top Insider Picks for 09/03/2024
Argus Research
3 months ago
Daily – Vickers Top Insider Picks for 08/30/2024
Simply Wall St.
3 months ago
Immix Biopharma Independent Director Acquires 2.6% More Stock
Compare IMMX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IMMX Immix Biopharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.